Michael V Chiorean MD
Advanced Endoscopic Interventional, Inflammatory Bowel Disease
Physician
Join to view full profile
5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Dr. Chiorean is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2000 - 2003- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2000
Corewell Health William Beaumont University HospitalInternship, Internal Medicine, 1997 - 1998
Iuliu Hatieganu University of Medicine and PharmacyClass of 1992
Certifications & Licensure
IL State Medical License 2026 - 2029
MI State Medical License 2025 - 2029
IN State Medical License 2004 - 2027
WA State Medical License 2012 - 2027
TX State Medical License 2023 - 2025
OH State Medical License 2004 - 2007
MN State Medical License 1999 - 2005
American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Splunk Enterprise, Splunk, Inc., 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Splunk, Splunk, Inc., 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2013-2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsEtrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program.Andres J Yarur, Michael V Chiorean, Jessica R Allegretti, Raymond K Cross, Christina Ha
Inflammatory Bowel Diseases. 2025-08-01 - 10 citationsImpact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés
Journal of Crohn's & Colitis. 2024-11-04 - 2 citationsPostvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease.Yoo Jin Lee, Dalin Li, Angela Mujukian, Philip Debbas, Melissa Hampton
Inflammatory Bowel Diseases. 2024-08-01
Press Mentions
FDA Approves Zeposia for Moderate-to-Severe Ulcerative ColitisMay 28th, 2021- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (Ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1May 27th, 2021
- One Physician's Take on CME in the Era of COVID: ACG 2020November 9th, 2020
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: